Merck Taps Nuevolution to Help Identify Drug Targets | GenomeWeb
NEW YORK (GenomeWeb News) – Nuevolution said today that it will use its DNA labeling platform to identify small-molecule leads against drug targets in a collaboration with Merck.
 
Copenhagen-based Nuevolution said it will use its Chemetics platform to screen multi-million member libraries for hit identification, and to perform hit-to-lead optimization.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.